Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ETHK Labs
华检医疗（1931.HK）

ETHK Labs Inc.
華檢醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1931)

PROFIT WARNING

This announcement is made by ETHK Labs Inc. (the "**Company**", and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary assessment of the Group's unaudited consolidated management accounts for the six months ended 30 June 2026 (the "**Reporting Period**") and the information currently available to the Board, it is expected that the Group will record a loss attributable to owners of the Company for the Reporting Period of not more than RMB74 million, representing a decrease of not more than RMB113.1 million for the Reporting Period as compared to the profit attributable to the owners of the Company of approximately RMB39.1 million for the six months ended 30 June 2025. The decrease in profit attributable to owners of the parent of the Group for the Reporting Period was primarily attributable to (i) an increase in administrative expenses of approximately RMB104.9 million due to increase in staff welfare and related expenses caused by the increase in staff headcounts; (ii) an increase in finance costs of approximately RMB38.5 million as a result of the increase in bank and other borrowings.; and (iii) an increase in provision for expected credit losses on trade and bills receivables and other receivables of approximately RMB34.3 million."

As the Company is still in the course of finalising the interim results of the Company for the Reporting Period, the information contained in this announcement is only based on a preliminary assessment by the Board with reference to the unaudited management accounts of the Group for the Reporting Period and the information currently available to the Board, which are yet to be finalized and have not been reviewed or audited by the Company's auditor nor reviewed by the audit committee of the Company and are subject to adjustments. The actual interim results of the Company for the Reporting Period may be different from disclosures in this announcement. Shareholders and potential investors are advised to refer to the interim results announcement for the Reporting Period, which is expected to be published on 31 August 2026.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
ETHK Labs Inc.
Lin Xianya
Executive Director

Hong Kong, 26 August 2026

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Ms. Yi Xiao, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and three independent non-executive directors, namely, Dr. Zhong Renqian, Mr. Xu Da and Mr. Zhang Jianlei.